Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCENTUATE: Evacetrapib for LDL-C Lowering
NCT02227784Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of evacetrapib in primary hyperlipidemia, sponsored by Eli Lilly and Company. Started Oct 2014; status: terminated.
02
Drugs
evacetrapib
03
Conditions
primary hyperlipidemia
Beyond the preview
Go deeper on NCT02227784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227784.